NCT07219030View on ClinicalTrials.gov

A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 8, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Healthy Volunteer
Interventions
DRUG

Emraclidine

Oral tablets

DRUG

Placebo

Oral tablets

Trial Locations (1)

60030

RECRUITING

ACPRU, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY